{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:56:51Z","timestamp":1790258211486,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.jss.2008.07.035","type":"journal-article","created":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T05:20:52Z","timestamp":1219900852000},"page":"705-713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rapamycin Inhibits Proliferation and Migration of Hepatoma Cells In Vitro"],"prefix":"10.1016","volume":"159","author":[{"given":"Yasumasa","family":"Shirouzu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Ryschich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Salnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vachtang","family":"Kerkadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2008.07.035_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ncponc0844","article-title":"Strategies for the management of hepatocellular carcinoma","volume":"4","author":"Schwartz","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jss.2008.07.035_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00000658-198804000-00002","article-title":"Liver transplantation for malignant disease. Results in 93 consecutive patients","volume":"207","author":"O'Grady","year":"1988","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2008.07.035_bib3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archsurg.1990.01410220045007","article-title":"Is liver transplantation justified for the treatment of hepatic malignancies?","volume":"125","author":"Olthoff","year":"1990","journal-title":"Arch Surg"},{"key":"10.1016\/j.jss.2008.07.035_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF01659064","article-title":"Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients","volume":"15","author":"Ringe","year":"1991","journal-title":"World J Surg"},{"key":"10.1016\/j.jss.2008.07.035_bib5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2005.07.019","article-title":"How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?","volume":"43","author":"Schwartz","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jss.2008.07.035_bib6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y","article-title":"Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation","volume":"68","author":"Yokoyama","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2008.07.035_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/SLA.0b013e318148c704","article-title":"Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA","volume":"246","author":"Duffy","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.jss.2008.07.035_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2008.07.035_bib9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.TP.0000120181.89206.54","article-title":"Pro- and anticancer effects of immunosuppressive agents used in organ transplantation","volume":"77","author":"Guba","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jss.2008.07.035_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/00007890-200212270-00017","article-title":"Low recurrence rate of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression?","volume":"74","author":"Vivarelli","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.jss.2008.07.035_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jss.2008.07.035_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.jss.2008.07.035_bib13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: Navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jss.2008.07.035_bib14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2008.07.035_bib15","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2008.07.035_bib16","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2008.07.035_bib17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jss.2008.07.035_bib18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI119038","article-title":"Rapamycin inhibits vascular smooth muscle cell migration","volume":"98","author":"Poon","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jss.2008.07.035_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0014-5793(03)00828-7","article-title":"Rapamycin inhibits GM-CSF-induced neutrophil migration","volume":"550","author":"Gomez-Cambronero","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jss.2008.07.035_bib20","doi-asserted-by":"crossref","first-page":"G510","DOI":"10.1152\/ajpgi.00189.2005","article-title":"Role of mTOR signaling in intestinal cell migration","volume":"291","author":"Rhoads","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jss.2008.07.035_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002112","article-title":"Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis","volume":"71","author":"Huber","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.jss.2008.07.035_bib22","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/jcb.20379","article-title":"Phosphorylated osteopontin promotes migration of human choriocarcinoma cells via a p70 S6 kinase-dependent pathway","volume":"94","author":"Al-Shami","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jss.2008.07.035_bib23","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Lang","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2008.07.035_bib24","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1038\/sj.onc.1209691","article-title":"Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways","volume":"25","author":"Liu","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jss.2008.07.035_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3748\/wjg.v11.i10.1420","article-title":"Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth","volume":"11","author":"Schumacher","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jss.2008.07.035_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.trim.2006.12.003","article-title":"Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro","volume":"17","author":"Zhang","year":"2007","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jss.2008.07.035_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/172460080602100103","article-title":"Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels","volume":"21","author":"Gershtein","year":"2006","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.jss.2008.07.035_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jss.2008.07.035_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(99)03882-9","article-title":"Sirolimus-tacrolimus combination immunosuppression","volume":"355","author":"McAlister","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2008.07.035_bib30","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","article-title":"Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma","volume":"10","author":"Kneteman","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jss.2008.07.035_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/jsre.2001.6145","article-title":"FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation","volume":"97","author":"Shah","year":"2001","journal-title":"J Surg Res"},{"key":"10.1016\/j.jss.2008.07.035_bib32","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Lang","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jss.2008.07.035_bib33","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jss.2008.07.035_bib34","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2008.07.035_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.jss.2008.07.035_bib36","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1681\/ASN.2006030196","article-title":"Chronic inhibition of mammalian target of rapamycin signaling down-regulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?","volume":"17","author":"Di Paolo","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jss.2008.07.035_bib37","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1126\/science.1064829","article-title":"Taking cell-matrix adhesions to the third dimension","volume":"294","author":"Cukierman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jss.2008.07.035_bib38","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1091\/mbc.01-12-0584","article-title":"Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake","volume":"13","author":"Edinger","year":"2002","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jss.2008.07.035_bib39","doi-asserted-by":"crossref","first-page":"H2861","DOI":"10.1152\/ajpheart.00561.2004","article-title":"Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin","volume":"288","author":"Sakakibara","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jss.2008.07.035_bib40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248040800499X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002248040800499X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:37:42Z","timestamp":1758379062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002248040800499X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S002248040800499X"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2008.07.035","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin Inhibits Proliferation and Migration of Hepatoma Cells In Vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2008.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}